Literature DB >> 12810422

Radiographic joint destruction in postmenopausal rheumatoid arthritis is strongly associated with generalised osteoporosis.

H Forsblad D'Elia1, A Larsen, E Waltbrand, G Kvist, D Mellström, T Saxne, C Ohlsson, E Nordborg, H Carlsten.   

Abstract

OBJECTIVES: To investigate determinants of joint destruction and reduced bone mineral density (BMD) in postmenopausal women with active rheumatoid arthritis (RA) not treated with bisphosphonates or hormone replacement therapy and to evaluate if there are common markers of erosive disease and bone loss.
METHODS: BMD was measured using dual x ray absorptiometry and joint damage was examined by x ray examination according to the Larsen method in 88 patients with RA. Associations between BMD and Larsen score, and between demographic and disease related variables, including proinflammatory cytokines, HLA-DR4 epitopes, and markers of bone and cartilage turnover, were examined bivariately by simple and multiple linear regression analyses.
RESULTS: 49/88 (56%) patients had osteoporosis in at least one site. Reduced BMD and increased joint destruction were associated with: at the forearm and femoral neck, high Larsen score, low weight, and old age (R(2)=0.381, p<0.001; R(2)=0.372, p<0.001, respectively); at the total hip, low weight, high Larsen score, and dose of injected glucocorticosteroids (R(2)=0.435, p<0.001); at the lumbar spine, low weight, reduced cartilage oligomeric matrix protein, and increased carboxyterminal propeptide of type I procollagen (R(2)=0.248, p<0.001). Larsen score was associated with long disease duration and increased C reactive protein (CRP) (R(2)=0.545, p<0.001).
CONCLUSIONS: Osteoporosis is common in postmenopausal patients with RA. Low weight and high Larsen score were strongly associated with BMD reduction. Increased CRP and long disease duration were determinants of erosive disease in postmenopausal women with RA. These findings indicate common mechanisms of local and generalised bone loss in RA.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12810422      PMCID: PMC1754591          DOI: 10.1136/ard.62.7.617

Source DB:  PubMed          Journal:  Ann Rheum Dis        ISSN: 0003-4967            Impact factor:   19.103


  44 in total

1.  A multicenter cross sectional study on bone mineral density in rheumatoid arthritis. Italian Study Group on Bone Mass in Rheumatoid Arthritis.

Authors:  L Sinigaglia; A Nervetti; Q Mela; G Bianchi; A Del Puente; O Di Munno; B Frediani; F Cantatore; R Pellerito; S Bartolone; G La Montagna; S Adami
Journal:  J Rheumatol       Date:  2000-11       Impact factor: 4.666

Review 2.  Pathogenesis of bone erosions in rheumatoid arthritis.

Authors:  S R Goldring; E M Gravallese
Journal:  Curr Opin Rheumatol       Date:  2000-05       Impact factor: 5.006

3.  Postmenopausal osteoporosis is more related to hormonal aberrations than to lifestyle factors.

Authors:  K Landin-Wilhelmsen; L Wilhelmsen; B A Bengtsson
Journal:  Clin Endocrinol (Oxf)       Date:  1999-10       Impact factor: 3.478

4.  The relationship between disease activity, joint destruction, and functional capacity over the course of rheumatoid arthritis.

Authors:  P M Welsing; A M van Gestel; H L Swinkels; L A Kiemeney; P L van Riel
Journal:  Arthritis Rheum       Date:  2001-09

5.  Bone mineral density and frequency of osteoporosis in female patients with rheumatoid arthritis: results from 394 patients in the Oslo County Rheumatoid Arthritis register.

Authors:  G Haugeberg; T Uhlig; J A Falch; J I Halse; T K Kvien
Journal:  Arthritis Rheum       Date:  2000-03

6.  Involvement of receptor activator of nuclear factor kappaB ligand/osteoclast differentiation factor in osteoclastogenesis from synoviocytes in rheumatoid arthritis.

Authors:  H Takayanagi; H Iizuka; T Juji; T Nakagawa; A Yamamoto; T Miyazaki; Y Koshihara; H Oda; K Nakamura; S Tanaka
Journal:  Arthritis Rheum       Date:  2000-02

7.  Synovial tissue in rheumatoid arthritis is a source of osteoclast differentiation factor.

Authors:  E M Gravallese; C Manning; A Tsay; A Naito; C Pan; E Amento; S R Goldring
Journal:  Arthritis Rheum       Date:  2000-02

8.  Low-dose prednisone therapy for patients with early active rheumatoid arthritis: clinical efficacy, disease-modifying properties, and side effects: a randomized, double-blind, placebo-controlled clinical trial.

Authors:  Amalia A van Everdingen; Johannes W G Jacobs; Dirk R Siewertsz Van Reesema; Johannes W J Bijlsma
Journal:  Ann Intern Med       Date:  2002-01-01       Impact factor: 25.391

Review 9.  Physiologic role of interleukin-1 receptor antagonist.

Authors:  W P Arend; C Gabay
Journal:  Arthritis Res       Date:  2000-05-19

Review 10.  Bone loss. Factors that regulate osteoclast differentiation: an update.

Authors:  S Roux; P Orcel
Journal:  Arthritis Res       Date:  2000-09-06
View more
  28 in total

1.  Generalized bone loss as a predictor of three-year radiographic damage in African American patients with recent-onset rheumatoid arthritis.

Authors:  Jie Zhang; David T Redden; Gerald McGwin; Leigh F Callahan; Edwin A Smith; Graciela S Alarcón; Larry W Moreland; Désirée M van der Heijde; Elizabeth E Brown; Donna K Arnett; Ted R Mikuls; S Louis Bridges
Journal:  Arthritis Rheum       Date:  2010-08

2.  The relation between joint erosion and generalized osteoporosis and disease activity in patients with rheumatoid arthritis.

Authors:  Filiz Sivas; Nurdan Barça; Mustafa Onder; Kürşat Ozoran
Journal:  Rheumatol Int       Date:  2006-04-20       Impact factor: 2.631

3.  Relation of interleukin-6 in rheumatoid arthritis patients to systemic bone loss and structural bone damage.

Authors:  Mona Helmy Abdel Meguid; Yousry Hasan Hamad; Rania Shafek Swilam; Mohamed Samy Barakat
Journal:  Rheumatol Int       Date:  2012-04-25       Impact factor: 2.631

4.  [Diagnosis and treatment of osteoporosis and rheumatoid arthritis in accordance with German guidelines. Results of a survey of patients, primary care physicians and rheumatologists].

Authors:  I Heberlein; W Demary; H Bloching; J Braun; F Buttgereit; R Dreher; C Kuhn; U Lange; A Zink; H Zeidler; H Häntzschel; H Raspe
Journal:  Z Rheumatol       Date:  2011-09       Impact factor: 1.372

5.  Up-regulation of the inflammatory response by ovariectomy in collagen-induced arthritis. effects of tin protoporphyrin IX.

Authors:  Lidia Ibáñez; Maria José Alcaraz; Nuria Maicas; David Guede; José Ramón Caeiro; Marije I Koenders; Wim B van den Berg; Maria Luisa Ferrándiz
Journal:  Inflammation       Date:  2011-12       Impact factor: 4.092

Review 6.  Clinical utilities of quantitative ultrasound in osteoporosis associated with inflammatory rheumatic diseases.

Authors:  Win Min Oo; Vasikaran Naganathan; Myat Thae Bo; David J Hunter
Journal:  Quant Imaging Med Surg       Date:  2018-02

7.  Correlation between hand bone mineral density and joint destruction in established rheumatoid arthritis.

Authors:  Takeshi Mochizuki; Koichiro Yano; Katsunori Ikari; Ryo Hiroshima; Yu Sakuma; Shigeki Momohara
Journal:  J Orthop       Date:  2017-08-02

8.  Influence of arthritis and non-arthritis related factors on areal bone mineral density (BMDa) in women with longstanding inflammatory polyarthritis: a primary care based inception cohort.

Authors:  Stephen R Pye; Tarnya Marshall; Karl Gaffney; Alan J Silman; Deborah P M Symmons; Terence W O'Neill
Journal:  BMC Musculoskelet Disord       Date:  2010-05-28       Impact factor: 2.362

9.  Bone mineral density in patients with recently diagnosed, active rheumatoid arthritis.

Authors:  M Güler-Yüksel; J Bijsterbosch; Y P M Goekoop-Ruiterman; J K de Vries-Bouwstra; H K Ronday; A J Peeters; J M de Jonge-Bok; F C Breedveld; B A C Dijkmans; C F Allaart; W F Lems
Journal:  Ann Rheum Dis       Date:  2007-04-24       Impact factor: 19.103

10.  Long term high intensity exercise and damage of small joints in rheumatoid arthritis.

Authors:  Z de Jong; M Munneke; A H Zwinderman; H M Kroon; K H Ronday; W F Lems; B A C Dijkmans; F C Breedveld; T P M Vliet Vlieland; J M W Hazes; T W J Huizinga
Journal:  Ann Rheum Dis       Date:  2004-11       Impact factor: 19.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.